Hudson Edge Investment Partners Inc. acquired a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29,255 shares of the medical instruments supplier's stock, valued at approximately $6,701,000. Becton, Dickinson and Company comprises about 1.4% of Hudson Edge Investment Partners Inc.'s portfolio, making the stock its 15th biggest position.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $27,000. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $29,000. REAP Financial Group LLC lifted its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Picton Mahoney Asset Management boosted its position in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $34,000. 86.97% of the stock is currently owned by institutional investors.
Insider Activity at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $964,107.36. The trade was a 8.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Trading Down 0.6%
NYSE:BDX traded down $1.11 on Friday, reaching $176.16. 1,057,606 shares of the company's stock were exchanged, compared to its average volume of 2,058,031. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The firm has a market capitalization of $50.49 billion, a price-to-earnings ratio of 33.62, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The business has a fifty day moving average of $174.52 and a 200-day moving average of $208.14.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. During the same quarter in the prior year, the business earned $3.17 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were issued a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.36%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.
Analyst Upgrades and Downgrades
BDX has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Barclays lowered their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Raymond James Financial downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Finally, Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average price target of $219.22.
Read Our Latest Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
